These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 15987078)

  • 1. [Individual monitoring of thiopurine and methotrexate treatment].
    Baslund B; Dalhoff KP; Schmiegelow K
    Ugeskr Laeger; 2005 May; 167(20):2177-9. PubMed ID: 15987078
    [No Abstract]   [Full Text] [Related]  

  • 2. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism and outcomes with azathioprine and 6-mercaptopurine.
    Gardiner SJ; Begg EJ; Barclay ML; Kirkpatrick CM
    Adverse Drug React Toxicol Rev; 2000 Dec; 19(4):293-312. PubMed ID: 11212460
    [No Abstract]   [Full Text] [Related]  

  • 4. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease.
    Bakker JA; Drent M; Bierau J
    Curr Opin Pulm Med; 2007 Sep; 13(5):458-63. PubMed ID: 17940494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease.
    Gearry RB; Barclay ML
    J Gastroenterol Hepatol; 2005 Aug; 20(8):1149-57. PubMed ID: 16048561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone marrow depression after azathioprine. New discoveries on an old drug].
    Löwhagen GB; Lindstedt G
    Lakartidningen; 2000 Feb; 97(5):458-62. PubMed ID: 10707497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Advances of research on the action of purinergic drugs and hereditary polymorphism of thiopurine methyltransferase].
    Liang A; Guo L
    Zhonghua Xue Ye Xue Za Zhi; 1998 Feb; 19(2):110-2. PubMed ID: 10921112
    [No Abstract]   [Full Text] [Related]  

  • 8. Weekly oral methotrexate therapy: raise awareness of fatal dosing errors.
    Prescrire Int; 2013 May; 22(138):126. PubMed ID: 23819175
    [No Abstract]   [Full Text] [Related]  

  • 9. Methotrexate.
    Held-Warmkessel J
    Clin J Oncol Nurs; 2000; 4(4):187-8. PubMed ID: 11261104
    [No Abstract]   [Full Text] [Related]  

  • 10. Advances in individual prediction of methotrexate toxicity: a review.
    Schmiegelow K
    Br J Haematol; 2009 Sep; 146(5):489-503. PubMed ID: 19538530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis.
    Warren RB; Griffiths CE
    Br J Dermatol; 2005 Nov; 153(5):869-73. PubMed ID: 16225593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methotrexate treatment in pediatric Crohn disease patients intolerant or resistant to purine analogues.
    Weiss B; Lerner A; Shapiro R; Broide E; Levine A; Fradkin A; Bujanover Y
    J Pediatr Gastroenterol Nutr; 2009 May; 48(5):526-30. PubMed ID: 19412004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Benefits and risks of immunosuppression in chronic inflammatory bowel diseases].
    Rogler G
    Dtsch Med Wochenschr; 2008 Sep; 133(38):1917-21. PubMed ID: 18785084
    [No Abstract]   [Full Text] [Related]  

  • 14. Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn's disease.
    Turner D; Grossman AB; Rosh J; Kugathasan S; Gilman AR; Baldassano R; Griffiths AM
    Am J Gastroenterol; 2007 Dec; 102(12):2804-12; quiz 2803, 2813. PubMed ID: 18042110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Teratogen update: azathioprine and 6-mercaptopurine.
    Polifka JE; Friedman JM
    Teratology; 2002 May; 65(5):240-61. PubMed ID: 11967923
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacogenetics of methotrexate in pediatric hematological neoplasm treatment: does it need a personalized regimen based on MTHFR polymorphisms?
    D'Angelo V; Ramaglia M; Iannotta A; Addeo R
    Expert Rev Hematol; 2014 Oct; 7(5):517-9. PubMed ID: 25213457
    [No Abstract]   [Full Text] [Related]  

  • 17. How should thiopurine treatment be monitored?--methodological aspects.
    Vikingsson S; Carlsson B; Almer S; Peterson C
    Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):278-83. PubMed ID: 20544507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nuclear winter.
    Lesesve JF; Mansuy L
    Transfusion; 2005 Sep; 45(9):1403. PubMed ID: 16131370
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical pharmacogenetics of methotrexate.
    Castaldo P; Magi S; Nasti AA; Arcangeli S; Lariccia V; Alesi N; Tocchini M; Amoroso S
    Curr Drug Metab; 2011 Mar; 12(3):278-86. PubMed ID: 21470106
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute renal insufficiency due to viral infection caused by cytomegalovirus (CMV) during treatment with methotrexate.
    Maiche AG
    Acta Oncol; 1995; 34(7):969-70. PubMed ID: 7492391
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.